American Journal of Clinical Dermatology

Papers
(The TQCC of American Journal of Clinical Dermatology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative167
The Current State of Systemic Therapy of Metastatic Uveal Melanoma164
Economic Burden of Chronic Hand Eczema: A Review146
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions137
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review103
Prognostic Biomarkers in Evolving Melanoma Immunotherapy97
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments87
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments86
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review82
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study77
The Burden of Pediatric Psoriasis: A Systematic Review75
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?72
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know72
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology70
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data56
Pathophysiology of Generalized Pustular Psoriasis56
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review54
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi53
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris52
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution52
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion51
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study49
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment48
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission48
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation46
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature46
Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”45
Inpatient Teledermatology Improves Diagnostic Accuracy and Management of Leg Ulcers in Hospitalized Patients45
Skin Cancer in People of Color: A Systematic Review44
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials44
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives42
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment40
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis40
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management40
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis39
A Practice Approach to Acne Fulminans in Adolescents38
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment Hist37
Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm37
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases36
A Review of the Etiologies and Key Clinical Features of Secondary Hyperhidrosis36
Patient and Public Involvement in Dermatology Research: A Review36
Scratching the Surface: A Comprehensive Guide to Understanding and Managing Vulvovaginal Itching36
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa34
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options34
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review33
Frontal Fibrosing Alopecia: An Update32
Oral Lichen Planus: An Update on Diagnosis and Management32
Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”32
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada32
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates32
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists31
Individualized Neoantigen-Directed Melanoma Therapy30
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History29
JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential28
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials28
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study28
Targeting Inflammation in Acne: Current Treatments and Future Prospects27
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)27
Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”25
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program25
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study24
Acknowledgement to Referees24
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea24
Identifying and Treating Ocular Manifestations in Psoriasis23
Management of Acne in Pregnancy23
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients23
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year23
Cutaneous Small Vessel Vasculitis: A Practical Guide to Diagnosis and Management23
Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study22
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion 22
Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review22
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians22
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey22
Approach to the Atypical Wound22
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials21
Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis21
Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)21
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results21
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study20
An Update on New and Existing Treatments for the Management of Melasma20
The 25th World Congress of Dermatology, Singapore, 3–8 July, 2023: Research Highlights20
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-220
Is There a Place for Biologics in Acne?19
Safety of Hydroxychloroquine: What a Dermatologist Should Know19
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study19
0.79472708702087